Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2021; 79(10): 895-899
DOI: 10.1590/0004-282X-ANP-2020-0315
Article

Motor symptoms and the quality of life of relapsing-remitting multiple sclerosis patients in a specialized center in South of Brazil

Sintomas motores e qualidade de vida em pacientes com esclerose múltipla remitente recorrente em um centro especializado no Sul do Brasil
Francielle Fontana Jorge 
1   Universidade Federal do Rio Grande do Sul, Curso de Fisioterapia, Porto Alegre RS, Brazil.
,
Alessandro Finkelsztejn 
2   Hospital de Clínicas de Porto Alegre, Porto Alegre RS, Brazil.
,
Luciano Palmeiro Rodrigues 
1   Universidade Federal do Rio Grande do Sul, Curso de Fisioterapia, Porto Alegre RS, Brazil.
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background: Spasticity, fatigue, muscle weakness and changes in gait are some of the main motor symptoms of Multiple Sclerosis (MS). These changes can interfere with the patients’ quality of life. Objective: To characterize the motor and quality of life symptoms in patients with relapsing-remitting Multiple Sclerosis at a specialized center. Methods: Fifty five patients at the Neuroimmunology Outpatient Clinic of the Hospital de Clínicas de Porto Alegre were evaluated for fatigue (Fatigue Severity Scale — FSS), walking ability (Functional Ambulation Categories — FAC), impact of MS on walking (Multiple Sclerosis Walking Scale-12 — MSWS-12), walking speed (10-Meter Walk Test — 10MWT and the Times 25-foot Walk test — T25FW), functional independence (Barthel Index — BI), functional mobility (Timed Up and Go — TUG), and quality of life (Multiple Sclerosis Impact Scale — MSIS-29). Results: The patients were mostly women (69.1%), with average age of 43.3 (±12.1) years old, with time since diagnosis of 8.2 (±5.3) years, and EDSS average of 4.3 (±1.3). On the BI, the mean was 96.6 (±5.7) points and 80% of the patients had FAC 5. At MSIS-29, patients had a higher average score on the psychological scale (19.5±26.7) than on the physical scale (10.2±23.6). Most patients (69.1%) presented fatigue. Conclusion: The patients had preserved functional independence and functional walking ability and presence of fatigue. There was minimal impact of MS on patients’ quality of life.

RESUMO

Antecedentes: Espasticidade, fadiga, fraqueza muscular e alterações na marcha são alguns dos principais sintomas motores da esclerose múltipla (MS). Essas alterações podem interferir na qualidade de vida dos pacientes. Objetivo: caracterizar os sintomas motores e qualidade de vida de pacientes com EM do tipo remitente-recorrente de um Centro Especializado. Métodos: Foram avaliados 55 pacientes do Ambulatório de Neuroimunologia do Hospital de Clínicas de Porto Alegre, quanto a fadiga (Escala de Severidade da Fadiga — FSS), capacidade de deambulação (Categoria de Deambulação Funcional — FAC), impacto da EM na caminhada (Multiple Sclerosis Walking Scale-12 — MSWS-12), velocidade de marcha (Teste de Caminhada de 10 Metros — 10MWT e o de Caminhada Cronometrada de 25 Pés — T25FW), independência funcional (Índice de Barthel — BI), mobilidade funcional (Timed Up and Go — TUG) e qualidade de vida (Escala de Impacto de Esclerose Múltipla — MSIS-29). Resultados: Os pacientes eram, em sua maioria, do sexo feminino (69,1%), com média de idade de 43,3 (±12,8) anos, tempo de diagnóstico de 8,2 (±5,3) anos e a média da EDSS de 4,3 (±1,3). A média no BI foi de 96,6 (±5,7) pontos e 80% dos pacientes apresentavam FAC 5. Na MSIS-29, os pacientes apresentaram maior pontuação média na escala psicológica (19,5±26,7) do que na física (10,2±23,6). A maioria dos pacientes (69.1%) apresentou fadiga. Conclusão: Os pacientes apresentaram independência funcional e capacidade de deambulação funcional preservadas e presença de fadiga. Houve pequeno impacto da EM na qualidade de vida dos pacientes.

Keywords:

Multiple Sclerosis - Fatigue - Gait - Quality of Life

Palavras-chave:

Esclerose Múltipla - Fadiga - Marcha - Qualidade de Vida

Authors’ contributions:

FFJ: data curation, formal analysis, investigation, methodology, writing of the original draft; AF: conceptualization, formal analysis, project administration; LPR: conceptualization, formal analysis, methodology, project administration, supervision, writing, review and editing.




Publication History

Received: 05 August 2020

Accepted: 02 November 2020

Article published online:
07 June 2023

© 2021. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol. 2014;122:15-58. https://doi.org/10.1016/B978-0-444-52001-2.00002-9
  • 2 Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014 Sep;83(11):1022-4. https://doi.org/10.1212/WNL.20200315202003150768
  • 3 Gama Pereira ABCN, Lacativa MCS, Costa Pereira FFC, Alvarenga RMP. Prevalence of multiple sclerosis in Brazil: a systematic review. Mult Scler Relat Disord. 2015 Nov;4(6):572-9. https://doi.org/10.1016/j.msard.2015.08.004
  • 4 Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018 Apr;391(10130):1622-36. https://doi.org/10.1016/S0140-6736(18)30481-1
  • 5 Kalincik T. Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology. 2015;44(4):199-214. https://doi.org/10.1159/000382130
  • 6 Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis–clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014 Mar;129(3):154-62. https://doi.org/10.1111/ane.12202
  • 7 Sebastião E, Sandroff BM, Learmonth YC, Motl RW. Validity of the timed up and go test as a measure of functional mobility in persons with multiple sclerosis. Arch Phys Med Rehabil. 2016 Jul;97(7):1072-7. https://doi.org/10.1016/j.apmr.2015.12.031
  • 8 Ramp M, Khan F, Misajon RA, Pallant JF. Rasch analysis of the multiple sclerosis impact scale (MSIS-29). Health Qual Life Outcomes. 2009 Jun;7:58. https://doi.org/10.1186/1477-7525-7-58
  • 9 Cardoso E, Fukuda T, Pereira J, Seixas J, Miranda R, Rodrigues B, et al. Clinical and epidemiological profile of multiple sclerosis in a reference center in the State of Bahia, Brazil. Arq Neuro-Psiquiatr. 2006 Sep;64(3B):727-30. https://doi.org/10.1590/S0004-282X2006000500005
  • 10 Grzesiuk AK. Características clínicas e epidemiológicas de 20 pacientes portadores de esclerose múltipla acompanhados em Cuiabá-Mato Grosso. Arq Neuro-Psiquiatr. 2006 Sep;64(3A):635-8. https://doi.org/10.1590/S0004-282X2006000400022
  • 11 Finkelsztejn A, Cristovam RA, Moraes GS, Lopes MGSM, Silva AV, Garcia MS, et al. Clinical features of multiple sclerosis in the south of Brazil: a partial analysis. Arq Neuro-Psiquiatr. 2009 Dec;67(4):1071-5. https://doi.org/10.1590/S0004-282X2009000600021
  • 12 Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 Oct;46(10):1121-3. https://doi.org/10.1001/archneur.1989.00520460115022
  • 13 Granger CV, Hamilton BB, Gresham GE, Kramer AA. The stroke rehabilitation outcome study: Part II. Relative merits of the total Barthel index score and a four-item subscore in predicting patient outcomes. Arch Phys Med Rehabil. 1989 Feb;70(2):100-3.
  • 14 Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability The 12-Item MS Walking Scale (MSWS-12). Neurology. 2003 Jan;60(1):31-6. https://doi.org/10.1212/wnl.60.1.31
  • 15 Mehrholz J, Wagner K, Rutte K, Meissner D, Pohl M. Predictive validity and responsiveness of the functional ambulation category in hemiparetic patients after stroke. Arch Phys Med Rehabil. 2007 Oct;88(10):1314-9. https://doi.org/10.1016/j.apmr.2007.06.764
  • 16 Oberg T, Karsznia A, Oberg K. Basic gait parameters: reference data for normal subjects, 10-79 years of age. J Rehabil Res Dev. 1993;30(2):210-23.
  • 17 Goldman MD, Motl RW, Scagnelli J, Pula JH, Sosnoff JJ, Cadavid D. Clinically meaningful performance benchmarks in MS Timed 25-Foot Walk and the real world. Neurology. 2013 Nov;81(21):1856-63. https://doi.org/10.1212/01.wnl.0000436065.97642.d2
  • 18 Podsiadlo D, Richardson S. The Timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991 Feb;39(2):142-8. https://doi.org/10.1111/j.1532-5415.1991.tb01616.x
  • 19 Lopes J, Kaimen-Maciel DR, Matsuo T. Adaptação transcultural e validação da Escala de Impacto de Esclerose Múltipla. Rev Neurocienc. 2011 Sep;19(3):433-40. https://doi.org/10.34024/rnc.2011.v19.8349
  • 20 Moreira MA, Felipe E, Endes MF, Tilbery CP. Esclerose múltipla. Arq Neuro-Psiquiatr. 2000 Jun;58(2B):460-66. https://doi.org/10.1590/S0004-282X220200315300010
  • 21 Bethoux F. Gait disorders in multiple sclerosis. Continuum (Minneap Minn). 2013 Aug;19(4 Multiple Sclerosis):1007-22. https://doi.org/10.1212/01.CON.0000433286.92596.d5
  • 22 Cameron MH, Wagner JM. Gait abnormalities in multiple sclerosis: pathogenesis, evaluation, and advances in treatment. Curr Neurol Neurosci Rep. 2011 Oct;11(5):507-15. https://doi.org/10.1007/s11910-011-0214-y
  • 23 Kurtzke JF. Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52. https://doi.org/10.1212/wnl.33.11.1444
  • 24 Van Asch, P Impact of mobility impairment in multiple sclerosis 2 – patients’ perspectives. Eur Neurol Rev. 2011 Jul;6(2):115-20. https://doi.org/10.17925/ENR.2011.06.02.115
  • 25 Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006 Mar;129(Pt 3):595-605. https://doi.org/10.1093/brain/awh714
  • 26 Marangoni BE, Pavan K, Tilbery CP. Cross-cultural adaptation and validation of the 12-item Multiple Sclerosis Walking Scale (MSWS-12) for the Brazilian population. Arq Neuro-Psiquiatr. 2012 Dec;70(12):922-8. https://doi.org/10.1590/S0004-282X2012001200004
  • 27 Williams AE, Vietri JT, Isherwood G, Flor A. Symptoms and association with health outcomes in relapsing-remitting multiple sclerosis: results of a US patient survey. Mult Scler Int. 2014;2014:203183. https://doi.org/10.1155/2014/203183
  • 28 Learmonth YC, Dlugonski DLA, Pilutti LA, Sandroff BM, Klaren R, Motl RW. Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale. J Neurol Sci. 2013 Aug;331(1-2):102-7. https://doi.org/10.1016/j.jns.2013.05.023
  • 29 Fiest KM, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, et al. Fatigue and comorbidities in multiple sclerosis. Int J MS Care. 2016 Mar-Apr;18(2):96-104. https://doi.org/10.7224/1537-2073.2015-070
  • 30 Chalah MA, Kauv P, Créange A, Hodel J, Lefaucheur JP, Ayache SS. Neurophysiological, radiological and neuropsychological evaluation of fatigue in multiple sclerosis. Mult Scler Relat Disord. 2019 Feb;28:145-52. https://doi.org/10.1016/j.msard.2018.12.029
  • 31 Rooney S, Wood L, Moffat F, Paul L. Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple Sclerosis. Mult Scler Relat Disord. 2019 Feb;28:276-82. https://doi.org/10.1016/j.msard.2019.01.011
  • 32 Benedetti MG, Piperno R, Simoncini L, Bonato P, Tonini A, Giannini S. Gait abnormalities in minimally impaired multiple sclerosis patients. Mult Scler. 1999 Oct;5(5):363-8. https://doi.org/10.1177/135245859900500510
  • 33 Casetta I, Riise T, Nortvedt MW, Economou NT, Gennaro R, Fazio P, Cesnik E, Govoni V, Granieri E. Gender differences in healthrelated quality of life in multiple sclerosis. Mult Scler. 2009 Nov;15(11):1339-46. https://doi.org/10.1177/1352458509107016